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doi:10.1016/j.jtcvs.2003.11.061130 The Journal of Thoracic and CardioObjectives: To test the hypothesis that patients with non–small cell lung cancer and
single-level N2 metastases constitute a favorable subgroup of patients with medi-
astinal metastases, we analyzed the results of the Eastern Cooperative Oncology
Group 3590 (a randomized prospective trial of adjuvant therapy in patients with
resected stages II and IIIa non–small cell lung cancer) by site of primary tumor and
pattern of lymph node metastases.
Methods: Accurate staging was ensured by mandating either systematic sampling or
complete dissection of the ipsilateral mediastinal lymph nodes. The overall survival
of patients with left lung non–small cell lung cancer and metastases in only 1 of
lymph node levels 5, 6, or 7 and right lung non–small cell lung cancer with
metastases in only 1 of levels 4 or 7 was compared with that of patients with N1
disease originating in the same lobe.
Results: The median survival of the 172 patients with single-level N2 disease was
35 months (95% confidence interval: 27-40 months) versus 65 months (95%
confidence interval: 45-84 months) for the 150 patients with N1 disease (median
follow-up 84 months, P  .01). However, among patients with left upper lobe
tumors, survival was not significantly different between patients with N1 disease
and patients with single-level N2 disease (49 vs 51 months, P  .63). The median
survival of the 71 patients with single-level N2 metastases without concomitant N1
disease (skip metastases) was 59 months (95% confidence interval: 36-107 months)
versus 26 months (95% confidence interval: 16-36 months) for the 145 patients with
both N1 and N2 metastases (P  .001).
Conclusions: Survival of patients with left upper lobe non–small cell lung cancer
and metastases to single-level N2 lymph nodes is not significantly different from
that of patients with N1 disease. The presence of isolate N2 skip metastases is
associated with improved survival when compared with patients with both N1 and
N2 disease. Survival should be reported by the lobe of primary tumor and metastatic
pattern to guide future clinical trial development, treatment strategies, and revisions
of the TNM staging system.
Controversy continues to surround the role of surgery for patientswith non–small cell lung cancer (NSCLC) and metastases to the N2lymph nodes. Although the clinical course of patients with resectedN2 disease has been extensively documented, definitive conclu-sions regarding the results of treatment are lacking. The continuedconfusion results from the dissimilar clinical and pathologic cate-
gories that comprise N2 disease.
Numerous factors seem to impact the survival of patients with resected N2
disease. Among them are the manner in which the N2 disease was identified, the
performance of mediastinoscopy, the thoroughness of intraoperative lymph node
assessment, the location of the lymph node, and the number of nodal levels
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TScontaining tumor. Finally, the fundamental definition of the
lymph node level location and boundaries will alter sur-
vival.
Intergroup Trial 0115 (Eastern Cooperative Oncology
Group 3590), a randomized prospective study of adjuvant
therapy after complete resection of stages II and IIIa
NSCLC, provided the opportunity to investigate the relation
of the number of positive N2 lymph node levels and the
pattern of nodal metastases to survival in patients who
underwent thorough staging of the mediastinal lymph nodes
and received uniform therapy.1
Materials and Methods
The Eastern Cooperative Oncology Group designed a randomized
prospective trial of adjuvant therapy to determine whether chemo-
radiotherapy was superior to radiotherapy alone in preventing local
recurrence and prolonging survival in patients with completely
resected stages II and IIIa NSCLC. The Radiation Therapy On-
cology Group, the North Central Treatment Group, the Cancer and
Leukemia Group B, and the Southwest Oncology Group were
active participants. The protocol was reviewed and approved by
the institutional review board or ethics committee at each site.
Written informed consent was obtained from either the patient or
his or her surrogate.
Patients who had undergone complete resection of pathologic
stages II (T1-2 N1 M0) or IIIa (T1-2 N2 M0, T3 N1-2 M0)
NSCLC were eligible for study participation. The International
Lung Cancer Staging System accepted by the American Joint
Committee on Cancer and the Union Internationale Contre Cancer
during the years 1986 to 1997 was used.2 Lymph node levels were
defined according to the American Thoracic Society.3 Level 10
was considered an N1 lymph node.
Complete mediastinal lymph node dissection or systematic
sampling was compulsory. The former was defined as resection of
all lymph nodes at specified levels, and the latter entailed the
removal of a representative lymph node at those same levels.
Dissection or sampling of levels 4, 7, and 10 was required during
a right thoracotomy and of levels 5 and/or 6 and 7 during a left
thoracotomy. To ensure uniform lymph node labeling and staging,
each operative note and pathology report was reviewed (S.M.K.).
Mediastinoscopy was required if the preoperative computed
tomography (CT) scan demonstrated mediastinal lymph nodes
greater than 1.5 cm in short axis diameter. Patients were ineligible
if mediastinoscopy revealed multilevel metastases, contralateral
mediastinal disease, or extranodal disease. Patients must have
undergone either lobectomy or pneumonectomy. Additional eligi-
bility requirements included a postoperative Eastern Cooperative
Oncology Group performance status of 0 or 1 and a postoperative
forced expiratory volume 1 sufficient to tolerate the proposed
radiotherapy.
Patients randomized to the control arm received 50.4 Gy in 28
daily 1.8-Gy fractions. The initial portion of the treatment was
administered with AP-PA portals from 36 Gy to 42 Gy. The
remainder of the treatment was given to the same target volume,
but with a lateral/oblique field arrangement that prevented the
spinal cord from receiving more than 45 Gy. The treatment arm
consisted of identical radiation treatment administered concomi-
The Journal of Thoracitantly with VP-16 (120 mg/m2 intravenously, days 1-3) and cis-
platin (60 mg/m2 intravenously, day 1). Chemotherapy was initi-
ated within 24 hours of radiotherapy and repeated every 28 days
for a total of 4 cycles. The frequency of follow-up physical
examinations and type of radiologic studies were not specified.
Statistical Analysis
Fisher’s exact test was used to compare groups with respect to
categoric end points (eg, recurrence).4 All P values reported from
the Fisher’s exact test are 2-tailed. Survival time was computed as
follows: Patients’ deaths are considered as events, and survival
time is the time to death from date of registration. Patients who are
alive are censored as of last known follow-up.
Survival distributions for survival time was estimated with the
Kaplan-Meier method5 and compared with the log-rank test.6 All
log-rank test P values reported are 2-tailed.
Results
A total of 488 patients were accrued to the study between
February 1991 and November 1997 (242 patients to the
radiotherapy arm and 246 patients to the chemoradiotherapy
arm). The median follow-up was 84 months. The median
survival of the 242 patients randomized to the radiotherapy
arm was 39 months (95% confidence interval [CI], 32-50
months), which was not significantly different from the
37-month median survival (95% CI, 31-43 months) of the
246 patients who received chemoradiotherapy (log rank,
P  .93). A review of the operative and pathology reports
revealed that the required intraoperative lymph node assess-
ment had been properly performed and documented in 373
patients. Analysis of this cohort revealed no survival differ-
ence between the 2 study arms.1 In the absence of an






Number of patients 150 172 44
Age (median, y) 62.1 60.7 63.3
Gender
Male 86 (57) 98 (57) 25 (57)
Female 64 (43) 74 (43) 19 (43)
Performance status
0 (fully active) 53 (35) 70 (40) 16 (36)
1 (ambulatory) 97 (65) 102 (60) 28 (64)
Treatment
Radiotherapy 68 (45) 79 (46) 21 (48)
Chemoradiotherapy 82 (55) 93 (64) 23 (52)
Histology
Squamous 68 (45) 54 (31) 15 (34)
Other 82 (55) 118 (69) 29 (66)
Lymph node assessment
Systematic sampling 74 (51) 97 (56) 13 (30)*
Complete dissection 76 (49) 75 (44) 33 (70)
*P  .01.identifiable survival advantage for either treatment arm, the
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analyzed by N status and primary tumor location.
N2 disease was documented in 223 patients, whereas 150
patients had tumors limited to the N1 lymph nodes. The
patient demographics appear in Table 1. The median sur-
vival was 65 months (95% CI, 45-84 months) for the
patients with N1 disease and 31 months (95% CI, 22-39
months) for all patients with N2 disease (log rank, P 
.003). The overall survival of patients with N1 disease was
significantly better than that of the 172 patients with tumor
limited to a single N2 station (median 35 months, log rank,
P .02) (Figure 1). Comparison of survival by N status and
lobe of primary tumor are given in Table 2. Survival of
patients with single-level N2 metastases and primary tumors
of the left upper lobe was not significantly different from
Figure 1. Median survival was 65.4 months (95% CI, 45-88.8
months) for patients with N1 disease and 30.6 months (95% CI,
22.3-38.6 months) for all patients with N2 disease; 5-year survivals
were 52% and 32%, respectively.









N1 47 87 .003
Single-level N2 61 36
Right lower
N1 25 45 .33
Single-level N2 34 28
Left upper
N1 43 49 .63
Single-level N2 49 51
Left lower
N1 28 56 .02
Single-level N2 28 27that of patients with N1 disease (Figure 2).
132 The Journal of Thoracic and Cardiovascular Surgery ● JulySurvival of patients with metastases to multiple N2 nodal
levels was not significantly different from that of patients
with single-level N2 metastases (Figure 3). The pattern of
N2 metastases is shown in Table 3. A comparison of sur-
vival by N status and lobe of primary tumor is given in
Table 4. The survival difference between patients with left
upper lobe tumors and single-level N2 disease and patients
with left upper lobe tumors and multiple-level N2 disease
approached statistical significance (Figure 4). Forty-three of
the 49 patients with left upper lobe tumors and single-level
N2 disease had metastases in the level 5 or 6 nodal stations.
Isolated N2 metastases without concomitant N1 disease
(skip metastases) were present in 71 patients. Survival of
this group was significantly better than that of patients who
had both N1 and N2 metastases (P  .001, Figure 5). The
benefit was, however, limited to patients with upper lobe
Figure 2. Median survival was 51.4 months (95% CI, 22.3 months–
not reached) for patients with left upper lobe tumors and single-
level N2 metastases and 49.4 months (95% CI, 25.4-89 months) for
patients with left upper lobe tumors and N1 disease; 5-year
survival was 42% in both groups.


















2 15 3 1 1
4 42 8 5 4
5 N/A N/A 47 11
6 N/A N/A 6 4
7 21 34 13 21
N/A, Not available.tumors (Table 5).
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Among all the categories of patients with N2 disease, those
found to have incidental mediastinal metastases at surgery
performed for clinical N0 disease have the best progno-
sis.7-13 Chest CT measured lymph nodes less than 1 cm in
transverse diameter and, more recently, negative positron
emission tomography (PET) scans appear to increase the
likelihood of regional rather than systemic disease. The
patients included in this study were all treated before the
availability of PET scanning but met the then-current defi-
nition of clinical N0 disease.
The manner in which the intraoperative assessment of
the mediastinal lymph nodes is conducted influences the
identification of metastatic lymph nodes and the total num-
ber of N2 lymph node levels that contain tumor.14,15 Sys-
Figure 3. Median survival was 20 months (95% CI, 14.3
35.3 months (95% CI, 26.9-39.9 months) for patients wit








Single-level N2 61 35 .45
Multiple-level N2 17 100
Right lower
Single-level N2 34 28 .46
Multiple-level N2 7 18
Left upper
Single-level N2 49 51 .06
Multiple-level N2 10 18
Left lower
Single-level N2 28 27 .49
Multiple-level N2 10 15tematic sampling seems as effective as complete mediasti-
The Journal of Thoracinal lymph node dissection in accurately determining the N
status, but complete node dissection identifies more levels
of N2 disease.16 Among the 373 patients in the present
study cohort, 187 underwent systematic dissection and 186
underwent complete node dissection. N1 disease was iden-
tified in 40% of patients and N2 disease was identified in
60% of patients who had undergone systematic sampling.
This was not significantly different from the 41% of patients
months) for patients with multi-level N2 disease and
gle-level N2 disease.
Figure 4. Median survival was 51.4 months (95% CI, 22.3 months–
not reached) for patients with left upper lobe tumors and single-
level N2 metastases and 18.2 months (95% CI, 7.6 months–not
reached) for patients with multiple-level N2 disease. The differ-
ence approximated statistical significance.-53.4
h sinwith N1 disease and 59% of patients with N2 disease found
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dissection. However, among the 222 patients with N2 me-
tastases, multiple levels of N2 disease were documented in
30% of patients who underwent complete node dissection
and 12% of patients who had systematic sampling.17
The extent of lymph node assessment may also influence
survival independently of the staging effect. Two random-
ized trials have demonstrated improved survival for patients
found to have N1 or N2 disease who underwent complete
node dissection when compared with systematic sam-
pling.16,18 Although the current study was not randomized,
improved survival was demonstrated for those patients who
underwent a complete mediastinal lymph node dissection.17
Although one pitfall of the current study is the under-
identification of the number of patients with multiple levels
Figure 5. Median survival was 58.8 months (95% CI, 35.5
compared with 25.6 months (95% CI, 16.2-35.9 months)
survivals were 50% and 18%, respectively.








Single-level N2 26 93 .01
N1  N2 52 27
Right lower
Single-level N2 11 39 .40
N1  N2 30 21
Left upper
Single-level N2 23 81 .09
N1  N2 36 22
Left lower
Single-level N2 11 13 .81
N1  N2 27 25of N2 disease and the different methods used to stage the
134 The Journal of Thoracic and Cardiovascular Surgery ● Julymediastinum, analysis of the effect of type of nodal assess-
ment by lobe and the number of nodal levels did not change
our conclusions.
The number of N2 levels containing tumor may be
inversely related to survival.8-11,19-22 Two studies have spe-
cifically compared patient survival by the number of in-
volved N2 levels. In both reports, the N2 disease was
considered “incidental,” discovered at surgery after a chest
CT failed to demonstrate enlarged (1 cm) mediastinal
lymph nodes. Andre and colleagues10 documented a median
survival of 30 months and a 5-year survival of 34% for 244
surgical patients with single-station N2 disease compared
with a median survival of 16 months and a 5-year survival
of 11% for 78 patients with multilevel N2 disease. Ichinose
and colleagues22 reported a 5-year survival of 43% for 209
patients who had not received induction therapy and who
were found to have single-level N2 disease, significantly
better than the 5-year survival of 17% for patients with
multiple-level N2 disease. Our data do not support the
contention that survival of patients with single-level N2
disease is uniformly superior to those with multiple-level
N2 disease, but rather it is lobar dependent.
The location of the involved lymph node levels in rela-
tion to the primary tumor seems to influence survival. Pa-
tients with right upper lobe tumors and metastases to the
ipsilateral level 4 lymph nodes have been reported to have
improved survival when compared with patients with sim-
ilar tumors and metastases to the level 7 lymph nodes.23
Patients with left upper lobe tumors and metastases to the
level 5 or 6 lymph nodes have survival similar to patients
with similar T status and N1 disease.24 In the current report,
7 months) for patients with solitary N2 skip metastases
patients with concomitant N1 and N2 disease; 5-year-106.
forwe are able to confirm that the survival of patients with left
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that of patients with N1 disease and superior to that of
patients with multiple levels of N2 metastases.
Skip metastases have been attributed to subpleural lym-
phatics that drain directly to the mediastinum. Numerous
investigators have documented improved survival in pa-
tients with skip metastases when compared with patients
with N1 and N2 disease.25-27 In this study, the survival
advantage was limited to patients with upper lobe tumors,
the lymphatic drainage of which is primarily to the paratra-
cheal lymph nodes (right lung tumors) or aortopulmonary
window lymph nodes (left lung tumors). The reason for
improved survival remains unclear, although patients with
skip metastases may have true regional disease that is ade-
quately treated with surgery.
The lymph node definitions and staging system are de-
signed to form homogeneous prognostic patient groups. As
more survival data have become available, the definitions
have been altered and the staging has been changed. The
survival differences among the various patient subgroups
with N2 disease are not adequately reflected in the current
definition of N2. The conclusions of this study are based on
secondary analysis of data obtained from a randomized trial
designed to answer an adjuvant therapy question and must
be interpreted as hypothesis-generating rather than defini-
tive. However, we believe that our findings merit consider-
ation in the design of future clinical trials and treatment
strategies. Future iterations of the TNM staging system
should account for the number of lymph node levels con-
taining metastatic tumor and the metastatic pattern.
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Discussion
Dr Garrett L. Walsh (Houston, Tex). The appropriate manage-
ment of patients with lung cancer with mediastinal disease remains
a complex and often confusing clinical problem for thoracic sur-
geons. The wide spectrum of N2 disease can be appreciated in 2
types of patients: One with bulky, multilevel involvement that is
clearly evident on a plain chest radiograph, frequently with a fixed
mediastinum on palpation at mediastinoscopy; the other with a
clinical stage I or II presentation with a normal chest radiograph
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easily removable, mobile nodes seen at surgery but with a small
microscopic focus of intranodal, single-station disease appreciated
only on final pathology. Both scenarios represent stage III disease.
Dr Keller and his colleagues present a very specific subset of
patients with completely resected stage II and stage III disease,
with appropriately staged mediastinums, who have already sur-
vived their operation to be enrolled in the adjuvant Eastern Coop-
erative Oncology Group trial. Their analysis demonstrates an im-
proved survival in patients with left upper lobe tumors with single-
station N2 disease comparable to patients with N1 disease that may
justify reclassifying aortopulmonary window nodes in left upper
lobe tumors as N1 disease.
Although this is an important analysis of a randomized trial, the
conclusions are not new. Dr Martini pointed out more than 20
years ago that patients with surgically resected single-station N2
disease had an improved prognosis over those with multilevel
mediastinal disease. Inferior mediastinal nodes had a worse prog-
nosis over nodes in upper mediastinal locations.
Dr Patterson and the Toronto group at the Society of Thoracic
Surgeons meeting in 1986 presented their experience with this
specific subset of patients with left upper lobe lesions with positive
subaortic lymph nodes. Their 5-year survival with completely
resected tumors and single-site N2 disease was also identical to
these data presented today (or 42% at 5 years).
Why do patients with left upper lobe lesions seem to do better?
Many of the patients in Patterson’s review and all of the patients
in this study received postoperative radiation therapy. Radiation
therapy is known to work better in tissues with an intact blood
supply. The patients with left upper lobe tumors in these 2 reports
would not have undergone sacrifice of the blood supply of the
paratracheal nodes as would occur in right-sided procedures with
mediastinal dissections of the level 4 nodes. Could the improve-
ment in survival for left upper lobe tumors in fact be a result of an
improved radiation therapy response and local control in medias-
tinal tissues that have not been surgically violated? I would be
interested in Dr Keller’s thoughts regarding this potential radia-
tion/biology explanation.
Although not described in the article, were there any other
characteristics of the primary left upper lobe tumors identified
through multivariate analysis that could contribute to the improved
survival, such as more favorable histology, smaller tumors, less
visceral pleural involvement, or female gender? Were the aorto-
pulmonary window nodes involved separately in all cases or were
some positive by direct extension from the left upper lobe lesions?
Was there a comparable number of lobectomies and pneumonec-
tomies performed for left upper lobe lesions compared with other
sites?
Although your analysis certainly will be helpful during the
postoperative discussion with patients when their final pathology is
available, how should we apply this knowledge to the patient who
will present to our office next week with a left upper lobe primary
with a clinically enlarged 1.5-cm aortopulmonary window node?
Let us assume that the patient is not hoarse and that his or her PET
scan demonstrates uptake only in the primary tumor and the node
but no other sites. Would you perform a cervical mediastinoscopy
and/or Chamberlain or VATS or FNA for this patient with clinical
stage IIIa or simply proceed to left upper lobectomy and medias-
136 The Journal of Thoracic and Cardiovascular Surgery ● Julytinal node dissection? If a stage III neoadjuvant protocol were
available, would this patient be an appropriate candidate or should
he or she be excluded on the basis of your survival data?
Although the emphasis has been on the left upper lobe tumors,
your table comparing N1 versus single-level N2 by primary tumor
lobe also shows no significant difference for right lower lobe
lesions. Although the median survival in right lower lobe N1
versus single-site N2 is 17 months apart, the statistics would argue
that your conclusions in the abstract should also apply to right
lower lobe primaries.
Finally, you state that improved survival in these single-station
N2 sites indicates the need to modify the current lung cancer
staging system. How would you realistically modify the present
staging system to take into account the anatomic or biologic
deviations that you have identified and still have a practical and
workable system?
Dr Keller. The paratracheal lymph nodes, levels 2 to 4, in the
patients analyzed in this study were less than 1 cm in diameter and
therefore unlikely to contain metastatic tumor. Therefore, I do not
believe that the theoretic advantage of radiating cancer-containing
tissues with an intact blood supply is a likely explanation for our
results.
We found no difference in gender, histology, or surgical pro-
cedure in patients who had left upper lobe tumors compared with
patients with other tumors. I do not have information regarding the
direct extension of tumor to the lymph nodes versus metastases
through lymphatic channels.
These data are not directed at the clinical situation that you
described, because all patients had mediastinal lymph nodes less
than 1 cm in diameter. However, in my practice, in a patient such
as you have described, with a 1.5-cm lymph node that is PET-
positive, I would proceed with surgery and not with other diag-
nostic procedures.
Our results would certainly have been much neater if the left
upper lobe was different from all the other lobes. The reason we
chose not to emphasize the right lower lobe was because the
difference in the median survival, although not significant, was
still very large (17 months). Although Dr Patterson and other
authors have demonstrated improved patient survival with resected
tumors of the left upper lobe and associated N2 metastases when
compared with the other lobes, there were no previously published
supporting data regarding improved survival of tumors in the right
lower lobe.
The staging system might be modified to take into consider-
ation the location of the primary tumor and the pattern of lymph
node metastases. For instance, level 5 or 6 lymph nodes would be
considered as N1 lymph nodes for patients with left upper lobe
tumors. In addition, stratification by lobe of the primary tumor and
the presence or absence of skip metastases may provide useful
information in interpreting the results of future adjuvant trials.
Dr Richard H. Feins (Rochester, NY). I certainly applaud your
continued massaging of the data from this intergroup trial, the only
phase III trial for lung cancer that has been reported since the end
of the Lung Cancer Study Group.
I would just ask you, from a practical standpoint, what do your
data tell you about the conduct of an operation so that one could
truly identify which patients have single-station N2 disease and
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sary to perform a complete lymph node dissection with frozen
sections of all tissue? Is a mediastinoscopy necessary for every-
body? Somewhere we have to come up with a strategy whereby the
thoracic surgeon can identify the subgroup of patients who are
going to have the improved survival.
Dr Keller. These patients were all enrolled in the original study
after surgery; therefore I do not have any data regarding the
specifics of their preoperative evaluation other than to say that all
the mediastinal lymph nodes were less than 1 cm in size. If the
lymph nodes were larger, the protocol mandated mediastinoscopy
to demonstrate that tumor was present only at a single nodal level.
Analysis of the data clearly demonstrated that systematic sampling
at defined lymph node levels stages the patients just as accurately
as a complete node dissection. However, a complete node dissec-
tion will identify more levels of N2 disease than a systematic
sampling.
Dr David H. Harpole, Jr (Durham, NC). I have a commentThe Journal of Thoraciaudience to realize that this is a very key study and that the authors
should be congratulated, because there have been very few large
multi-institutional cooperative group studies in which a surgeon
has had a very significant role. Dr Keller and his group have done
a great job of not only getting this trial designed and finished but
also examining surgical issues in respect to the results of the trial
as opposed to just the usual medical/oncology issues. So I think we
all need to appreciate the hard work that went into this.
Now, putting on my clinical trials hat, I have to remind the
audience as well that, unfortunately, although as provocative as
these data are (and I think there is some truth in these findings, and
it is important to follow up on them), when one does a subset
analysis on data sets that were not included in the primary and
secondary objectives of a trial, the statisticians will tell you that
sometimes the data do not necessarily tell the whole truth. The
outcomes from the Z30 American College of Surgeons Oncology
Group trial, which looks at the randomization of nodal dissection
and sampling, will be able to add more information with respect toG
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